1Department of health and human services U.S. Food and drug Ad- ministration. Section 201.57. Specific requirements on content and format of labeling for human prescription drug and biological prod- ucts. Part 201 Labeling Title 21 Code of Federal Regulations USA [ EB/OL ]. http://www, accessdata, fda. gov/scripts/cdrh/cfdocs/ cfcfr/CFRSearch, cfm? fr = 201.56. 2010 - 04 - 01.
2FDA. Guidance for Industry Labeling for Human rescription Drug and Biological Products --Implementing the New Content and Format Re- quirements [ EB/OL ]. http://www, fda. gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm 075082. pdf. 2006 -01 - 18.
3BOEHRINGER INGELHEIM. The prescribing information for MICAR- DIS (telmisartan) Tablets. http://www, accessdata, fda. gov/drug- satfda_docs/label/2011/020850s0321b1, pdf. 2011 - 07 - 06.
4FDA. Guidance for Industry Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims[EB/OL]. http://www, fda. gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid- ances/UCM075072, pdf. 2011 - 03 - 14.
5KING PHARMS. The prescribing information for ALTACE Tablets (ramipril). http ://www. accessdata, fda. gov/drugsaffda_does/label/ 2011/022021 s0071b1, pdf. 2011 - 08 - 04.
